artemisinin
Artemisinin and its semisynthetic derivatives are a group of drugs used in the treatment of malaria due to Plasmodium falciparum. It was discovered in 1972 by Tu Youyou, who shared the 2015 Nobel Prize in Physiology or Medicine for her discovery. Artemisinin-based combination therapies (ACTs) have become standard treatment worldwide for P. falciparum malaria as well as malaria due to other species of Plasmodium. Artemisinin can be extracted from the herb Artemisia annua, which is used in traditional Chinese medicine. Alternatively, it can be prepared by a semi-synthetic method from a precursor compound that can be produced using a genetically engineered yeast, which is much more efficient than extraction from the plant. — Wikipedia
Clinical trial activity
25 trials · 41 clinical orgs · 0 marketing orgs
Earliest trial started Aug 31, 2008 (NCT00753506)
Timeline
Indications
Approved for
Studied for
- Anus Neoplasms · Phase 2
- Carcinoma · Phase 2
- Coronavirus · Phase 2
- Coronavirus Infections · Phase 3
- COVID-19 · Phase 4
- Drug Combinations · Phase 1
- Genital Neoplasms, Female · Phase 2
- Healthy Volunteers · Phase 1
- Lupus Erythematosus, Systemic · Phase 2
- Malaria · Phase 4
- Malaria, Falciparum · Phase 4
- Malaria, Vivax · Phase 4
- Neoplasms · Phase 2
- Papillomavirus Infections · Phase 2
- Parasitic Diseases · Phase 4
- Pharmacokinetics · Phase 1
- Plasmodium falciparum · Phase 4
- Schizophrenia · Phase 3
- Severe Acute Respiratory Syndrome · Phase 3
- Vulvar Diseases · Phase 2
- Vulvar Neoplasms · Phase 2
Mechanism of action
- Unspecified targetOTHER
Unknown
Chemistry & pharmacology
SMILES
C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4- Mol. weight
- 282.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaArtemisinin ↗
- ChEMBLCHEMBL567597 ↗
- ChEMBLCHEMBL269671 ↗
Also known as
- arteannuin
- arteannuin
- artemef
- artemisin
- artemisin
- artemisine
- artemisinin
- artemisinin
- artemisinin
- artemisinin
- artemisinin
- artemisinin
- artemisinin
- artemisinin
- (+)-artemisinin
- (+)-artemisinin
- (+)-artemisinin
- artemisinine
- artemisinine
- artemisinine
- gnf-pf-5341
- gnf-pf-5341
- qinghaosu
- quinghaosu
- quing hau sau
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06173206 | Phase 3 | Mar 15, 2024 | University of London |
| NCT06166498 | Phase 3 | Feb 15, 2024 | University of London |
| NCT06206564 | Phase 2 | Jan 12, 2024 | Anal Dysplasia Clinic MidWest, Frantz Medical |
| NCT06075264 | Phase 2 | Dec 6, 2023 | Frantz Medical, The Cleveland Clinic |
| NCT04802382 | Phase 3 | Jun 11, 2021 | MGC Pharmaceuticals |
| NCT04801017 | Phase 2 | Apr 30, 2021 | Oncotelic Inc. |
| NCT04428385 | N/A | Oct 31, 2020 | Clinton Health Access Initiative, USA, Duke University, Moi Univeristy, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04428307 | N/A | Oct 31, 2020 | Clinton Health Access Initiative, USA, Duke University, Moi Univeristy, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05004753 | Phase 4 | Sep 30, 2020 | Mateon Therapeutics, Windlas Healthcare |
| NCT04387240 | Phase 2 | Jun 30, 2020 | Princess Nourah Bint Abdulrahman University |
| NCT04382040 | Phase 2 | May 8, 2020 | MGC Pharmaceuticals |
| NCT04020653 | Phase 2 | Sep 6, 2019 | Neopharma, Parexel |
| NCT03951259 | Phase 2 | May 15, 2019 | Jiangsu ZuoYou Medicine Co., Ltd., Jiao Tong University |
| NCT04167566 | N/A | Jul 1, 2017 | Noguchi Memorial Institute for Medical Research, World Health Organization |
| NCT02653898 | Phase 4 | Jan 1, 2016 | Government of Cambodia, Government of Thailand, National Center for Parasitology, Entomology and Malaria Control |
| NCT02568098 | Phase 1 | Oct 1, 2015 | Mahidol University, University of Oxford |
| NCT02604966 | Phase 4 | Apr 1, 2015 | Institute of Tropical Medicine, Belgium, National Institute of Malariology, Parasitology and Entomology, Vietnam, University of Antwerp |
| NCT02118090 | Phase 4 | May 1, 2014 | Institut Pasteur, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01930331 | Phase 4 | Sep 1, 2013 | Ifakara Health Institute |
| NCT01838902 | Phase 3 | Aug 1, 2013 | Medical Research Council, Medical Research Council, The Gambia |